Evonik Industries Announces 2015 Results and 2016 Expectations

"We have been successful in the orderly implementation of the growth strategy by's strong performance in the fourth quarter of 2015, with the full-year targetv9dChairman, DrInkaiShi"
v9dThe business should continue to be successful despite the tough market conditions in 2016, with adjusted EBITDA expected to be between 2 billion and 2.2 billion eurosv9d
Evonik Industries Group recently announced its 2015 financial results, and last year's full-year performance was excellent, fulfilling expectationsv9d
"Our strategy is to invest heavily in new manufacturing facilities and innovation to achieve organic growth in our businessThis strategy has brought success to both the company and its shareholders"The chairman of Evonik Industrial Group, DrInkaiShi, said at the main data report for fY2015 v9d
　　Despite weak global economic growth and an unoptimistic overall trend in the chemical industry, Evonik has achieved strong revenue growth "Thanks to our understanding of our customers' specific needs, we are able to provide our customers with targeted products and solutions Dr Inkes explained v9d
　　FY15 Key Data v9d sales increased 5% to EUR 13.5 billion (2014: EUR 12.9 billion) adjusted EBITDA of EUR 2.47 billion, in line with expectations, and represented a significant increase of 31% (2014: EUR 1.19 billion) in the two major growth sectors , Nutrition and Consumer Chemicals and Resource Efficiency , both of which achieved revenues , although revenues were slightly lower than the same period last year v9d
　　Adjusted EBITDA margin was particularly strong in the chemical industry, reaching 18.2% (2014:14.6%) return on invested capital (ROCE) of 16.6%, indicating a significant return on capital v9d
　　Adjusted net income increased 44 percent to EUR 1,128 million (2014: EUR 782 million) as a result of strong operating performance, with free cash flow of EUR 1,052 million after capital expenditure v9d
　　Strong operating performance and planned execution of growth investments have enabled Evonik to achieve excellent ROCE and high free cash flow "Capital efficiency and cash flow will continue to be a top priority for Winstart in the future Ute Wolf, Evonik's chief financial officer, said v9d
　　Actively address inglising to the challenges of 2016
v9d early 2016, the global economy is weak, markets are highly volatile and geopolitical tensions are rising Despite the broader environment, Evonik expects the market to maintain a high level of demand for its products, thanks in large part to its dominant market position and strategy of focusing on high-growth businesses v9d
　　However, the increase in sales volume will be offset by a decrease in sales prices, resulting in a small decline in sales Adjusted EBITDA for 2016 is expected to be between EUR 2 billion and EUR 2.2 billion v9d
　　To consolidate the growth base v9d Evonik will strongly support the growth of the amino acid and methionine market, according to market demand in a timely manner to expand production capacity On March 2, 2016, Evonik's supervisory board approved the preparation of the preliminary phase of the construction of a new methionine plant in Singapore, as well as the acquisition of the Norwegian company MedPalett AS By acquiring the nutritional supplement maker, Evonik will further advance the strategic development of its food and pharmaceutical raw materials business v9d
　　At the same time, Evonik will expand its film business for the future market by building a new hollow fiber spinning plant in Sch?rfling, Austria, to produce gas separation film components for energy efficiency v9d
　　"We have been successful in the orderly implementation of the growth strategy by achieving our full-year target v9d ," said Dr Inkai, Chairman of the V9d , which performed strongly in the fourth quarter of 2015 "
v9d The business should continue to be successful despite the tough market conditions in 2016, with adjusted EBITDA expected to be between 2 billion and 2.2 billion euros v9d
　　Evonik Industries Group recently announced its 2015 financial results, and last year's full-year performance was excellent, fulfilling expectations v9d
　　"Our strategy is to invest heavily in new manufacturing facilities and innovation to achieve organic growth in our business This strategy has brought success to both the company and its shareholders "The chairman of Evonik Industrial Group, Dr InkaiShi, said at the main data report for fY2015 v9d
　　Despite weak global economic growth and an unoptimistic overall trend in the chemical industry, Evonik has achieved strong revenue growth "Thanks to our understanding of our customers' specific needs, we are able to provide our customers with targeted products and solutions Dr Inkes explained v9d
　　FY15 Key Data v9d sales increased 5% to EUR 13.5 billion (2014: EUR 12.9 billion) adjusted EBITDA of EUR 2.47 billion, in line with expectations, and represented a significant increase of 31% (2014: EUR 1.19 billion) in the two major growth sectors , Nutrition and Consumer Chemicals and Resource Efficiency , both of which achieved revenues , although revenues were slightly lower than the same period last year v9d
　　Adjusted EBITDA margin was particularly strong in the chemical industry, reaching 18.2% (2014:14.6%) return on invested capital (ROCE) of 16.6%, indicating a significant return on capital v9d
　　Adjusted net income increased 44 percent to EUR 1,128 million (2014: EUR 782 million) as a result of strong operating performance, with free cash flow of EUR 1,052 million after capital expenditure v9d
　　Strong operating performance and planned execution of growth investments have enabled Evonik to achieve excellent ROCE and high free cash flow "Capital efficiency and cash flow will continue to be a top priority for Winstart in the future Ute Wolf, Evonik's chief financial officer, said v9d
　　Actively address inglising to the challenges of 2016
v9d early 2016, the global economy is weak, markets are highly volatile and geopolitical tensions are rising Despite the broader environment, Evonik expects the market to maintain a high level of demand for its products, thanks in large part to its dominant market position and strategy of focusing on high-growth businesses v9d
　　However, the increase in sales volume will be offset by a decrease in sales prices, resulting in a small decline in sales Adjusted EBITDA for 2016 is expected to be between EUR 2 billion and EUR 2.2 billion v9d
　　To consolidate the growth base v9d Evonik will strongly support the growth of the amino acid and methionine market, according to market demand in a timely manner to expand production capacity On March 2, 2016, Evonik's supervisory board approved the preparation of the preliminary phase of the construction of a new methionine plant in Singapore, as well as the acquisition of the Norwegian company MedPalett AS By acquiring the nutritional supplement maker, Evonik will further advance the strategic development of its food and pharmaceutical raw materials business v9d
　　At the same time, Evonik will expand its film business for the future market by building a new hollow fiber spinning plant in Sch?rfling, Austria, to produce gas separation film components for energy efficiency v9d
Share it on feed